FM (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR.

The [R]-FM regimen consists of:

  1. (R)ituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones;
  2. (F)ludarabine - an antimetabolite;
  3. (M)itoxantrone - a synthetic antracycline analogue (an antraquinone) that is able to intercalate DNA and prevent mitosis.[1]

This regimen is also sometimes used in some autoimmune disorders that are inherently sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis).

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(F)ludarabine 25 mg/m2 IV infusion Days 1-3
(M)itoxantrone 10 mg/m2 IV infusion Day 1